SG10201907399RA - Enhanced delivery of viral particles to the striatum and cortex - Google Patents
Enhanced delivery of viral particles to the striatum and cortexInfo
- Publication number
- SG10201907399RA SG10201907399RA SG10201907399RA SG10201907399RA SG10201907399RA SG 10201907399R A SG10201907399R A SG 10201907399RA SG 10201907399R A SG10201907399R A SG 10201907399RA SG 10201907399R A SG10201907399R A SG 10201907399RA SG 10201907399R A SG10201907399R A SG 10201907399RA
- Authority
- SG
- Singapore
- Prior art keywords
- striatum
- cortex
- enhanced delivery
- viral particles
- particles
- Prior art date
Links
- 210000001577 neostriatum Anatomy 0.000 title abstract 4
- 239000002245 particle Substances 0.000 title abstract 4
- 230000003612 virological effect Effects 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 210000003710 cerebral cortex Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0085—Brain, e.g. brain implants; Spinal cord
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562114544P | 2015-02-10 | 2015-02-10 | |
US201562220997P | 2015-09-19 | 2015-09-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201907399RA true SG10201907399RA (en) | 2019-09-27 |
Family
ID=56614902
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201706445SA SG11201706445SA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
SG10201907399RA SG10201907399RA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
SG10201912926VA SG10201912926VA (en) | 2015-02-10 | 2016-02-10 | Enhanced delivery of viral particles to the striatum and cortex |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201706445SA SG11201706445SA (en) | 2015-02-10 | 2016-02-09 | Enhanced delivery of viral particles to the striatum and cortex |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912926VA SG10201912926VA (en) | 2015-02-10 | 2016-02-10 | Enhanced delivery of viral particles to the striatum and cortex |
Country Status (27)
Country | Link |
---|---|
US (2) | US20190111157A1 (ja) |
EP (3) | EP4219728A3 (ja) |
JP (3) | JP6928558B2 (ja) |
KR (2) | KR20240010539A (ja) |
CN (2) | CN107530447A (ja) |
AU (2) | AU2016219398A1 (ja) |
BR (1) | BR112017017037A2 (ja) |
CA (1) | CA2976082A1 (ja) |
CL (1) | CL2017002028A1 (ja) |
CR (1) | CR20170407A (ja) |
DK (1) | DK3256594T3 (ja) |
EA (1) | EA201791803A1 (ja) |
ES (1) | ES2904504T3 (ja) |
HK (1) | HK1246340A1 (ja) |
HU (1) | HUE057272T2 (ja) |
IL (3) | IL296466A (ja) |
LT (1) | LT3256594T (ja) |
MX (2) | MX2017010370A (ja) |
PH (1) | PH12017501436A1 (ja) |
PL (1) | PL3256594T3 (ja) |
PT (1) | PT3256594T (ja) |
RS (1) | RS62811B1 (ja) |
SG (3) | SG11201706445SA (ja) |
SI (1) | SI3256594T1 (ja) |
TN (1) | TN2017000353A1 (ja) |
TW (1) | TWI730952B (ja) |
WO (1) | WO2016130591A2 (ja) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
SG10202007103TA (en) | 2014-11-05 | 2020-09-29 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
CA2975583A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
US10597660B2 (en) | 2014-11-14 | 2020-03-24 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
WO2016094783A1 (en) | 2014-12-12 | 2016-06-16 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scaav |
BR112017017037A2 (pt) * | 2015-02-10 | 2018-04-10 | Genzyme Corp | liberação realçada de partículas virais para o estriado e córtex |
TWI707951B (zh) | 2015-04-08 | 2020-10-21 | 美商健臻公司 | 過大腺相關載體之製造 |
US11020443B2 (en) | 2015-04-23 | 2021-06-01 | University Of Massachusetts | Modulation of AAV vector transgene expression |
GB201508025D0 (en) | 2015-05-11 | 2015-06-24 | Ucl Business Plc | Fabry disease gene therapy |
IL257939B2 (en) | 2015-09-24 | 2023-03-01 | Biomarin Pharm Inc | Adeno-associated virus factor 8 vectors, associated virus particles, and medicinal formulations comprising the same |
WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
CA3024448A1 (en) | 2016-05-18 | 2017-11-23 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
EP3458589A4 (en) | 2016-05-18 | 2020-01-01 | Voyager Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR TREATING HUNTINGTON'S DISEASE |
JP2019531787A (ja) | 2016-08-30 | 2019-11-07 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 生物医学的ターゲティング及びデリバリーの方法並びにそれを実行するための装置及びシステム |
EP3519569B1 (en) * | 2016-09-30 | 2020-12-02 | Esteve Pharmaceuticals, S.A. | Adenoassociated virus vectors for the treatment of mucopolysaccharidoses |
CN110770344A (zh) * | 2017-03-31 | 2020-02-07 | 舒泰神(北京)生物制药股份有限公司 | shRNA表达框、携带其的多核苷酸序列及其应用 |
WO2018191450A2 (en) | 2017-04-14 | 2018-10-18 | National Taiwan University Hospital | Gene therapy for aadc deficiency |
CA3061368A1 (en) * | 2017-05-05 | 2018-11-08 | Voyager Therapeutics, Inc. | Compositions and methods of treating huntington's disease |
AU2018261790A1 (en) | 2017-05-05 | 2019-11-28 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (ALS) |
JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
US11497576B2 (en) | 2017-07-17 | 2022-11-15 | Voyager Therapeutics, Inc. | Trajectory array guide system |
CA3071978A1 (en) | 2017-08-03 | 2019-02-07 | Voyager Therapeutics, Inc. | Compositions and methods for delivery of aav |
EP3697908A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
EP3697905A1 (en) | 2017-10-16 | 2020-08-26 | Voyager Therapeutics, Inc. | Treatment of amyotrophic lateral sclerosis (als) |
CN113476484A (zh) * | 2018-06-29 | 2021-10-08 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
CA3117982A1 (en) * | 2018-11-14 | 2020-05-22 | Bhargavi KONDRAGUNTA | Gene therapy for neuronal ceroid lipofuscinoses |
CN113710281A (zh) * | 2019-02-22 | 2021-11-26 | 宾夕法尼亚州大学信托人 | 用于治疗grn相关成人发作性神经退行性病变的重组腺相关病毒 |
EP3983077A4 (en) * | 2019-06-17 | 2023-12-20 | Alnylam Pharmaceuticals, Inc. | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM |
WO2021007382A1 (en) * | 2019-07-09 | 2021-01-14 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of parkinson's disease |
WO2021016505A1 (en) * | 2019-07-24 | 2021-01-28 | Voyager Therapeutics, Inc. | Compositions and methods for treating huntington's disease |
WO2021177116A1 (ja) * | 2020-03-02 | 2021-09-10 | 国立大学法人群馬大学 | ミクログリア選択的遺伝子発現ベクター |
KR20220153021A (ko) * | 2020-03-11 | 2022-11-17 | 리모터 테라퓨틱스, 인코포레이티드 | 중추신경계를 통한 단백질을 확산시키기 위한 방법 및 재료 |
AU2022212922A1 (en) * | 2021-01-27 | 2023-08-17 | Research Institute At Nationwide Children's Hospital | Materials and methods for the treatment of lysosomal acid lipase deficiency (lal-d) |
EP4323531A1 (en) | 2021-04-12 | 2024-02-21 | Affinia Therapeutics Inc. | Recombinant aav for treatment of neural disease |
WO2023113806A1 (en) | 2021-12-16 | 2023-06-22 | Affinia Therapeutics, Inc. | Recombinant aav for treatment of neural disease |
WO2023108507A1 (en) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Recombinant aav vectors and use thereof |
WO2023109911A1 (en) * | 2021-12-15 | 2023-06-22 | National Institute Of Biological Sciences, Beijing | Microglia having car and use thereof |
WO2024086747A1 (en) | 2022-10-19 | 2024-04-25 | Affinia Therapeutics Inc. | Recombinant aavs with improved tropism and specificity |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4692147A (en) | 1980-04-02 | 1987-09-08 | Medtronic, Inc. | Drug administration device |
US5735815A (en) | 1993-07-26 | 1998-04-07 | Sentinel Medical, Inc. | Method of using fluid jet surgical cutting tool |
EP0931158A1 (en) | 1996-09-06 | 1999-07-28 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
US6042579A (en) | 1997-04-30 | 2000-03-28 | Medtronic, Inc. | Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain |
US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
ES2257051T3 (es) | 1998-05-27 | 2006-07-16 | Avigen, Inc. | Administracion potenciada por conveccion de vectores aav que codifican aadc. |
ES2308989T3 (es) | 1999-08-09 | 2008-12-16 | Targeted Genetics Corporation | Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios. |
EP1290205B1 (en) | 2000-06-01 | 2006-03-01 | University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
PL220644B1 (pl) | 2001-11-13 | 2015-11-30 | Univ Pennsylvania | Wirus stowarzyszony z adenowirusem (AAV), kompozycja, wyizolowane białko kapsydowe, wyizolowane lub syntetyczne cząsteczki kwasu nukleinowego, sposób wytwarzania zrekombinowanego wirusa, komórka gospodarza |
GB2389791B (en) | 2002-04-30 | 2006-12-13 | Steven Gill | Implantable drug delivery pump |
SI2277996T1 (sl) | 2003-05-21 | 2014-12-31 | Genzyme Corporation | Postopki za izdelavo pripravkov rekombinantnih AAV virionov v bistvu brez praznih kapsid |
CN102626336A (zh) | 2004-10-05 | 2012-08-08 | 建新公司 | 台阶式插管 |
US8283151B2 (en) | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
JP5829372B2 (ja) * | 2005-05-02 | 2015-12-09 | ジェンザイム・コーポレーション | 神経代謝性疾患のための遺伝子治療 |
US9089667B2 (en) | 2005-08-23 | 2015-07-28 | The Regents Of The University Of California | Reflux resistant cannula and system for chronic delivery of therapeutic agents using convection-enhanced delivery |
EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
US7922999B2 (en) | 2006-04-25 | 2011-04-12 | The Regents Of The University Of California | Administration of growth factors for the treatment of CNS disorders |
JP2009535360A (ja) | 2006-04-26 | 2009-10-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 高分子量神経治療薬の対流増加送達のための組成物および方法 |
CA2751266A1 (en) | 2009-01-29 | 2010-08-05 | Krystof Bankiewicz | Methods for distributing high levels of therapeutic agent throughout the cortex to treat neurological disorders |
SI3067417T1 (sl) | 2009-06-16 | 2018-11-30 | Genzyme Corporation | Izboljšani postopki čiščenja vektorjev rekombinantnega AAV |
US8663624B2 (en) | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
EP2673286B1 (en) * | 2011-02-12 | 2019-07-03 | University of Iowa Research Foundation | Therapeutic compounds |
KR101956885B1 (ko) | 2011-02-17 | 2019-03-12 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 조직 특이성 변경 및 aav9-매개 유전자 전달 개선을 위한 조성물 및 방법 |
ES2879636T3 (es) * | 2014-05-02 | 2021-11-22 | Genzyme Corp | Vectores AAV para la terapia génica de la retina y el SNC |
BR112017017037A2 (pt) * | 2015-02-10 | 2018-04-10 | Genzyme Corp | liberação realçada de partículas virais para o estriado e córtex |
-
2016
- 2016-02-09 BR BR112017017037A patent/BR112017017037A2/pt active Search and Examination
- 2016-02-09 SI SI201631446T patent/SI3256594T1/sl unknown
- 2016-02-09 WO PCT/US2016/017210 patent/WO2016130591A2/en active Application Filing
- 2016-02-09 HU HUE16714066A patent/HUE057272T2/hu unknown
- 2016-02-09 EP EP23150591.8A patent/EP4219728A3/en active Pending
- 2016-02-09 CN CN201680020700.4A patent/CN107530447A/zh active Pending
- 2016-02-09 ES ES16714066T patent/ES2904504T3/es active Active
- 2016-02-09 SG SG11201706445SA patent/SG11201706445SA/en unknown
- 2016-02-09 RS RS20220044A patent/RS62811B1/sr unknown
- 2016-02-09 CA CA2976082A patent/CA2976082A1/en active Pending
- 2016-02-09 CR CR20170407A patent/CR20170407A/es unknown
- 2016-02-09 KR KR1020247000976A patent/KR20240010539A/ko active Application Filing
- 2016-02-09 EP EP21198081.8A patent/EP4023758A1/en not_active Withdrawn
- 2016-02-09 AU AU2016219398A patent/AU2016219398A1/en not_active Abandoned
- 2016-02-09 CN CN202210805297.3A patent/CN116019934A/zh active Pending
- 2016-02-09 SG SG10201907399RA patent/SG10201907399RA/en unknown
- 2016-02-09 EP EP16714066.4A patent/EP3256594B1/en active Active
- 2016-02-09 PL PL16714066T patent/PL3256594T3/pl unknown
- 2016-02-09 MX MX2017010370A patent/MX2017010370A/es unknown
- 2016-02-09 EA EA201791803A patent/EA201791803A1/ru unknown
- 2016-02-09 KR KR1020177025285A patent/KR102625784B1/ko active IP Right Grant
- 2016-02-09 LT LTEPPCT/US2016/017210T patent/LT3256594T/lt unknown
- 2016-02-09 PT PT167140664T patent/PT3256594T/pt unknown
- 2016-02-09 US US15/549,962 patent/US20190111157A1/en not_active Abandoned
- 2016-02-09 DK DK16714066.4T patent/DK3256594T3/da active
- 2016-02-09 IL IL296466A patent/IL296466A/en unknown
- 2016-02-09 TN TNP/2017/000353A patent/TN2017000353A1/en unknown
- 2016-02-09 JP JP2017560479A patent/JP6928558B2/ja active Active
- 2016-02-10 SG SG10201912926VA patent/SG10201912926VA/en unknown
- 2016-02-15 TW TW105104342A patent/TWI730952B/zh active
-
2017
- 2017-08-08 CL CL2017002028A patent/CL2017002028A1/es unknown
- 2017-08-08 IL IL253894A patent/IL253894B/en unknown
- 2017-08-10 PH PH12017501436A patent/PH12017501436A1/en unknown
- 2017-08-10 MX MX2021004294A patent/MX2021004294A/es unknown
-
2018
- 2018-04-25 HK HK18105355.8A patent/HK1246340A1/zh unknown
-
2021
- 2021-07-22 IL IL285060A patent/IL285060B2/en unknown
- 2021-08-06 JP JP2021129519A patent/JP2021178861A/ja active Pending
-
2022
- 2022-06-28 AU AU2022204583A patent/AU2022204583A1/en active Pending
- 2022-07-29 US US17/816,139 patent/US20220395586A1/en active Pending
-
2023
- 2023-02-10 JP JP2023018846A patent/JP2023058630A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501436A1 (en) | Enhanced delivery of viral particles to the striatum and cortex | |
PH12018500594A1 (en) | Adeno-associated virus factor viii vectors, associated viral particles and therapeutic formulations comprising the same | |
IL259595B1 (en) | Gradual methods for the production of a recombinant adenovirus (aav) vector in a serum-free suspension cell culture system suitable for clinical use | |
MX2022012490A (es) | Vectores de aav para la terapia genica de la retina y el snc. | |
SG10201909381WA (en) | Production of oversized adeno-associated vectors | |
BR112015021884A8 (pt) | vetores de plasmídeo recombinantes, partícula viral avv ou pluralidade de partículas virais, seus métodos de produção e seus usos, e composição farmacêutica | |
MX2020010694A (es) | Particulas de raav que codifican mir-708 y usos del mismo. | |
MX2018004755A (es) | Entrega de polinucleotidos dirigidos al sistema nervioso central. | |
NZ704275A (en) | Aav-mediated gene therapy for rpgr x-linked retinal degeneration | |
MX365835B (es) | Uso de akkermansia para tratar trastornos metabolicos. | |
MX2019005266A (es) | Composiciones, metodos y usos de transferencia genetica para tratar enfermedades neurodegenerativas. | |
SG10201902285SA (en) | Adeno-associated viral vectors for treating myocilin (myoc) glaucoma | |
MX2018003234A (es) | Metodos y materiales para la terapia genica galgt2. | |
WO2014145524A3 (en) | Compositions and methods for immune tolerance induction to factor viii replacement therapies in subjects with hemophilia a | |
MX2020003042A (es) | Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa. | |
MA40818B2 (fr) | Administration améliorée de particules virales au striatum et au cortex | |
WO2013006514A3 (en) | Recombinant adeno-associated virus-mediated expression of fractalkine for treatment of neuroinflammatory and neurodegenerative diseases | |
TN2016000460A1 (en) | Aav vectors for retinal and cns gene therapy. | |
NZ764033A (en) | Aav vectors for retinal and cns gene therapy |